Academic Content and Language Evaluation of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (10770)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
May 15, 2018 (publication date) through Feb 17, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastrointestinal Oncology
ISSN
1948-5204
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Contratto M, Wu J. Targeted therapy or immunotherapy? Optimal treatment in hepatocellular carcinoma. World J Gastrointest Oncol 2018; 10(5): 108-114 [PMID: 29770170 DOI: 10.4251/wjgo.v10.i5.108] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5204/full/v10/i5/108.htm |
| Number | Citing Articles |
| 1 |
Tae Ho Hong, M. T. Jeena, Ok-Hee Kim, Kee-Hwan Kim, Ho Joong Choi, Kyung Hee Lee, Ha-Eun Hong, Ja-Hyoung Ryu, Say-June Kim. Application of self-assembly peptides targeting the mitochondria as a novel treatment for sorafenib-resistant hepatocellular carcinoma cells. Scientific Reports 2021; 11(1) doi: 10.1038/s41598-020-79536-z
|
| 2 |
Hong‐fu Liu, Yuan‐kang Xie, Bai‐yin Zhong, Jian‐hong Zhang, Cai‐xin Song, Yu‐wen Liu, Yan Yang, Bin‐hui Xie. Dipeptidyl peptidase‐8 induces sorafenib resistance via binding with c‐Rel to mediate NF‐κB signaling in hepatocellular carcinoma. Cell Biology International 2022; 46(2): 213 doi: 10.1002/cbin.11719
|
| 3 |
H.H. Rashwan, A.M. Taher, H.A. Hassan, A.A. Awaji, C.J. Kiriacos, R.A. Assal, R.A. Youness. Harnessing the supremacy of MEG3 LncRNA to defeat gastrointestinal malignancies. Pathology - Research and Practice 2024; 256: 155223 doi: 10.1016/j.prp.2024.155223
|
| 4 |
Shima Ghavimi, Tehila Apfel, Hamed Azimi, Alana Persaud, Nikolaos T. Pyrsopoulos. Management and Treatment of Hepatocellular Carcinoma with Immunotherapy: A Review of Current and Future Options. Journal of Clinical and Translational Hepatology 2020; 8(2): 168 doi: 10.14218/JCTH.2020.00001
|
| 5 |
Yong Zhou, Ren-Gen Fan, Cheng-Lin Qin, Jing Jia, Xu-Dong Wu, Wen-Zhang Zha. LncRNA-H19 activates CDC42/PAK1 pathway to promote cell proliferation, migration and invasion by targeting miR-15b in hepatocellular carcinoma. Genomics 2019; 111(6): 1862 doi: 10.1016/j.ygeno.2018.12.009
|
| 6 |
Jonathan Tibballs, Warren Clements. Immunotherapy and Transarterial therapy of HCC: What the interventional radiologist needs to know about the changing landscape of HCC treatment?. Journal of Medical Imaging and Radiation Oncology 2022; 66(4): 478 doi: 10.1111/1754-9485.13405
|
| 7 |
Shengnan Liu, Yang Du, He Ma, Qian Liang, Xu Zhu, Jie Tian. Preclinical comparison of regorafenib and sorafenib efficacy for hepatocellular carcinoma using multimodality molecular imaging. Cancer Letters 2019; 453: 74 doi: 10.1016/j.canlet.2019.03.037
|
| 8 |
Zhaonan Liu, Xingjie Li, Xuequn He, Yingchun Xu, Xi Wang. Complete response to the combination of Lenvatinib and Pembrolizumab in an advanced hepatocellular carcinoma patient: a case report. BMC Cancer 2019; 19(1) doi: 10.1186/s12885-019-6287-8
|
| 9 |
Weiwei Ke, Hongbo Wang, Xiangxuan Zhao, Zaiming Lu. Foeniculum vulgare seed extract exerts anti-cancer effects on hepatocellular carcinoma. Food & Function 2021; 12(4): 1482 doi: 10.1039/D0FO02243H
|
| 10 |
Mengmeng Wang, Zhifan Xiong. The Mutation and Expression Level of LRP1B are Associated with Immune Infiltration and Prognosis in Hepatocellular Carcinoma. International Journal of General Medicine 2021; : 6343 doi: 10.2147/IJGM.S333390
|
| 11 |
Xiaohong Cen, Kui Cheng. Ter‐cell, A New Target for Hepatocellular Carcinoma Therapy. ChemBioChem 2018; 19(21): 2254 doi: 10.1002/cbic.201800410
|
| 12 |
Innere Medizin Differenzialdiagnostik und Differenzialtherapie. 2021; : 503 doi: 10.1016/B978-3-437-21921-4.00246-4
|
| 13 |
Jun-Shan Liu, Chu-Ying Huo, Hui-Hui Cao, Chun-Lin Fan, Jian-Yang Hu, Li-Juan Deng, Zi-Bin Lu, Hua-Yi Yang, Lin-Zhong Yu, Zhi-Xian Mo, Zhi-Ling Yu. Aloperine induces apoptosis and G2/M cell cycle arrest in hepatocellular carcinoma cells through the PI3K/Akt signaling pathway. Phytomedicine 2019; 61: 152843 doi: 10.1016/j.phymed.2019.152843
|
| 14 |
Yang Shi, Xiaohua Yang, Xiaofeng Xue, Ding Sun, Peng Cai, Qingwei Song, Bin Zhang, Lei Qin. HANR promotes lymphangiogenesis of hepatocellular carcinoma via secreting miR‐296 exosome and regulating EAG1/VEGFA signaling in HDLEC cells. Journal of Cellular Biochemistry 2019; 120(10): 17699 doi: 10.1002/jcb.29036
|
| 15 |
Yu-Chen Chuang, Jen-Chih Tseng, Li-Rung Huang, Chun-Ming Huang, Chi-Ying F. Huang, Tsung-Hsien Chuang. Adjuvant Effect of Toll-Like Receptor 9 Activation on Cancer Immunotherapy Using Checkpoint Blockade. Frontiers in Immunology 2020; 11 doi: 10.3389/fimmu.2020.01075
|
| 16 |
Yongzheng Xu, Chuandong Sun, Bing Han, Yue Xi, Mao Zhang, Jing Yang, Zongkai Chen. High KIAA1522 expression predicts a poor prognosis in patients with hepatocellular carcinoma. Oncology Letters 2020; 20(1): 509 doi: 10.3892/ol.2020.11588
|
| 17 |
Qing‐Quan Liu, Yu‐Wen Liu, Yuan‐Kang Xie, Jian‐Hong Zhang, Cai‐Xin Song, Jian‐Zhong Wang, Bin‐Hui Xie. Amplification of DDR2 mediates sorafenib resistance through NF‐κB/c‐Rel signaling in hepatocellular carcinoma. Cell Biology International 2021; 45(9): 1906 doi: 10.1002/cbin.11625
|
| 18 |
T. Mocan, Z. Sparchez, R. Craciun, C. N. Bora, D. C. Leucuta. Programmed cell death protein-1 (PD-1)/programmed death-ligand-1 (PD-L1) axis in hepatocellular carcinoma: prognostic and therapeutic perspectives. Clinical and Translational Oncology 2019; 21(6): 702 doi: 10.1007/s12094-018-1975-4
|
| 19 |
Mahmoud A. Younis, Ikramy A. Khalil, Mahmoud M. Abd Elwakil, Hideyoshi Harashima. A Multifunctional Lipid-Based Nanodevice for the Highly Specific Codelivery of Sorafenib and Midkine siRNA to Hepatic Cancer Cells. Molecular Pharmaceutics 2019; 16(9): 4031 doi: 10.1021/acs.molpharmaceut.9b00738
|
| 20 |
Lincy S. Lal, Abdalla Aly, Lisa B. Le, Susan Peckous, Brian Seal, April Teitelbaum. Healthcare costs related to adverse events in hepatocellular carcinoma treatment: A retrospective observational claims study. Cancer Reports 2022; 5(5) doi: 10.1002/cnr2.1504
|
| 21 |
Miltiadis Krokidis, Danae Fakitsa, Katerina Malagari, Theodoros Karampelas, Demosthenes Fokas, Constantin Tamvakopoulos, Achilles Chatziioannou. Combination of Doxorubicin and Antiangiogenic Agents in Drug-Eluting Beads: In Vitro Loading and Release Dynamics in View of a Novel Therapeutic Approach for Hepatocellular Carcinoma. CardioVascular and Interventional Radiology 2024; 47(5): 661 doi: 10.1007/s00270-024-03714-z
|
| 22 |
Zhi Liu, Jian Yu Chen, Yang Zhong, Liang Xie, Jian Shui Li. lncRNA MEG3 inhibits the growth of hepatocellular carcinoma cells by sponging miR-9-5p to upregulate SOX11. Brazilian Journal of Medical and Biological Research 2019; 52(10) doi: 10.1590/1414-431x20198631
|
| 23 |
Ching Ngar Wong, Petros Fessas, Kathy Dominy, Francesco A. Mauri, Takahiro Kaneko, Persephone Du Parcq, Jamshid Khorashad, Pierluigi Toniutto, Robert D. Goldin, Claudio Avellini, David J. Pinato. Qualification of tumour mutational burden by targeted next‐generation sequencing as a biomarker in hepatocellular carcinoma. Liver International 2021; 41(1): 192 doi: 10.1111/liv.14706
|